India-UK Trade Agreement Raises Concerns

The article elaborates on the implications of the India-United Kingdom Comprehensive Economic and Trade Agreement (CETA), specifically focusing on the provisions related to intellectual property, particularly concerning access to affordable medicines through licensing mechanisms. Here is a detailed summary:

Summary:

1. CETA Overview:

   • The India-UK CETA has raised concerns over India's commitments, especially in Chapter 13, which addresses intellectual property.
   • Article 13.6 specifically emphasizes the preference for voluntary licensing over compulsory licensing for ensuring access to medicines.

2. Compulsory vs. Voluntary Licensing:

   • India traditionally advocated for compulsory licensing to combat high prices of patented medicines, allowing local production to improve affordability.
   • A significant case was the 2012 grant of compulsory license to Natco Pharma for sorafenib tosylate, which reduced treatment costs from ₹2,80,428 to ₹8,800.

3. Legislative Background:

   • India's Patents Act was amended to align with the WTO TRIPS Agreement, which permits compulsory licensing after three years from the patent grant.
   • The legislation allows compulsory licenses if the patented invention is either not satisfying reasonable public requirements or not available at affordable prices in India.

4. Impact of CETA:

   • India's commitment to voluntary licensing as per CETA would undermine its longstanding position advocating for compulsory licensing in international forums.
   • This shift weakens a key provision of the 2001 Doha Declaration, which allows member countries to issue compulsory licenses amid public health crises.

5. Concerns with Voluntary Licensing:

   • Critics argue that voluntary licensing does not adequately ensure affordable access to medicines, citing the weak negotiating power of domestic companies against multinational pharmaceutical firms.
   • The experience with Cipla's remdesivir, produced under a voluntary license from Gilead Sciences, showed pricing higher than that set by Gilead in the U.S., highlighting the limitations of voluntary arrangements.

6. Technology Transfer Issues:

   • CETA's provisions may compromise India's demand for technology transfer on favorable terms, a demand reiterated in various multilateral discussions, including the UN's NIEO resolution (1974), aimed at facilitating technology sharing with developing nations for industrialization.
   • India's Fourth Biennial Update Report to the UNFCCC (2024) noted that barriers such as slow technology transfer and stringent IPR impede the adoption of climate-friendly technologies.

7. Constitutional and International Implications:

   • The change in stance might affect India's leverage in future negotiations regarding technology transfer essential for tackling climate change and promoting industrial development.
   • The article emphasizes the need for India to reassess its position on compulsory licensing to ensure health security and sustainable technological advancements.

Key Points:

• The India-UK CETA impacts India's position on intellectual property, particularly concerning medicines access.
• Voluntary licensing is favored in CETA, opposing India's historical support for compulsory licensing.
• Compulsory licensing was pivotal in reducing medicine prices significantly in the past.
• The Doha Declaration reaffirms the right to issue compulsory licenses, a stance India now weakens by conceding to voluntary licensing.
• Concerns about the effectiveness of voluntary licensing highlighted by price disparities in past cases.
• Technology transfer issues related to climate change and industrialization are at risk due to concessions made in CETA.
• India's demands for favorable terms in technology transfer could be adversely affected, impacting its developmental strategies.

The article indicates the necessity for India to strike a balance between complying with international trade agreements while safeguarding public health interests and advancing its industrial capabilities.